Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES
Status:
Not yet recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
Our local IRB approved clinical studies seeking proof of principle for the hypothesis that
SFN can be safely administered to humans at doses sufficient to protect age-associated
cardiac dysfunctions. Beneficial effects of SFN-therapy will be assessed by Pre- and
post-intervention echocardiography, and exercise endurance at 0 and 24 weeks. Peripheral
blood cells from treated and control subjects will be compared for mitochondrial respiratory
function, oxidative damage, pro-inflammatory cytokines, and expression of antioxidant &
anti-electrophile genes.